Polymorphisms associated with apolipoprotein B levels in Greek patients with familial hypercholesterolemia

References

1. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 1982; 66:335–62.10.1016/S0025-7125(16)31424-9Search in Google Scholar

2. Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis 1992; 96:91–107.10.1016/0021-9150(92)90056-MSearch in Google Scholar

3. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154–6.10.1038/ng1161Search in Google Scholar PubMed

4. Golstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beadet AL, Sly W, Valle D, editors. The metabolic and molecular basis of inherited disease, 7th ed. New York: McGraw-Hill, 1995.Search in Google Scholar

5. Dedoussis GV, Genschel J, Bochow B, Pitsavos C, Skoumas J, Prassa M, et al. Molecular characterization of familial hypercholesterolemia in German and Greek patients. Hum Mutat 2004; 23:285–6.10.1002/humu.9218Search in Google Scholar PubMed

6. Dedoussis GV, Skoumas J, Pitsavos C, Choumerianou DM, Genschel J, Schmidt H, et al. FH clinical phenotype in Greek patients with LDL-R defective vs. negative mutations. Eur J Clin Invest 2004; 34:402–9.10.1111/j.1365-2362.2004.01351.xSearch in Google Scholar PubMed

7. Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defesche JC, et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998; 97:729–35.10.1161/01.CIR.97.8.729Search in Google Scholar PubMed

8. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998; 18:309–15.10.1161/01.ATV.18.2.309Search in Google Scholar PubMed

9. Wittekoek ME, Moll E, Pimstone SN, Trip MD, Lansberg PJ, Defesche JC, et al. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19:2708–13.10.1161/01.ATV.19.11.2708Search in Google Scholar

10. Bertolini S, Pisciotta L, Di Scala L, Langheim S, Bellocchio A, Masturzo P, et al. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 2004; 174:57–65.10.1016/j.atherosclerosis.2003.12.037Search in Google Scholar PubMed

11. Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498–509.10.1006/geno.1996.0225Search in Google Scholar PubMed

12. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998; 213:149–57.10.1016/S0378-1119(98)00193-0Search in Google Scholar

13. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276:44444–9.10.1074/jbc.M105660200Search in Google Scholar

14. Fisher RM, Humphries SE, Talmaud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atheroscleosis 1997; 135:145–59.10.1016/S0021-9150(97)00199-8Search in Google Scholar

15. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70:138–43.10.1055/s-0038-1646175Search in Google Scholar

16. de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, et al. –455G-A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998; 18:265–71.10.1161/01.ATV.18.2.265Search in Google Scholar

17. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38:87–104.10.1016/S0033-0620(05)80001-5Search in Google Scholar

18. Schmidt HW, Pollock JS, Nakane M, Gorsky LD, Förstermann U, Murad F. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA 1991; 88:365–9.10.1073/pnas.88.2.365Search in Google Scholar

19. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, et al. T-786→C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99:2864–70.10.1161/01.CIR.99.22.2864Search in Google Scholar

20. Koller E, Koller F, Binder BR. Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. J Biol Chem 1989; 264:12412–8.10.1016/S0021-9258(18)63874-8Search in Google Scholar

21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.10.1093/nar/16.3.1215Search in Google Scholar PubMed PubMed Central

22. Cheng S, Pallaud C, Grow MA, Klitz W, Erlich HA, Visvikis S, et al. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med 1998; 36:561–6.10.1515/CCLM.1998.096Search in Google Scholar

23. Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M. Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat 1996; 8:168–77.10.1002/(SICI)1098-1004(1996)8:2<168::AID-HUMU9>3.0.CO;2-7Search in Google Scholar

24. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62:36–44.10.1086/301669Search in Google Scholar

25. Leus FR, Zwart M, Kastelein JJ, Voorbij HA. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001; 154:641–9.10.1016/S0021-9150(00)00440-8Search in Google Scholar

26. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Gen 1991; 40:277–82.10.1111/j.1399-0004.1991.tb03096.xSearch in Google Scholar

27. Reymer PW, Groenemeyer BE, Gagne E, Miao L, Appelman EE, Seidel JC, et al. Hum Mol Genet 1995; 4:1543–9.10.1093/hmg/4.9.1543Search in Google Scholar

28. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A metaanalysis. Circulation 1999; 99:2901–7.10.1161/01.CIR.99.22.2901Search in Google Scholar

29. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a liporpotein-associated protein, K-45: identity of K-45 paraoxonase. Eur J Biochem 1993; 211:871–9.10.1111/j.1432-1033.1993.tb17620.xSearch in Google Scholar

30. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterio-scler Thromb Vasc Biol 1998; 18:84–91.10.1161/01.ATV.18.1.84Search in Google Scholar

31. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001; 157:123–9.10.1016/S0021-9150(00)00717-6Search in Google Scholar

32. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44:37–42.10.2337/diab.44.1.37Search in Google Scholar

33. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94:2057–63.10.1161/01.CIR.94.9.2057Search in Google Scholar

34. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997; 99:3034–9.10.1172/JCI119499Search in Google Scholar

35. Lam TH, Liu LJ, Janus ED, Bourke C, Hedley AJ. The relationship between fibrinogen and other coronary heart disease risk factors in a Chinese population. Atherosclerosis 1999; 143:405–13.10.1016/S0021-9150(98)00294-9Search in Google Scholar

36. Henry I, Uzan G, Weil D, Nicholas H, Kaplan JC, Marguerie G, et al. The genes coding for the Aα, Bβ and γ chain of fibrinogen map to 4q2. Am J Hum Genet 1984; 36:760–8.Search in Google Scholar

37. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152:897–907.10.1093/aje/152.10.897Search in Google Scholar

38. Brown ET, Fuller GM. Detection of a complex that associates with the Bβ fibrinogen G–455–A polymorphism. Blood 1998; 92:3286–93.10.1182/blood.V92.9.3286Search in Google Scholar

39. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P, et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 2001; 38:1054–61.10.1161/hy1101.092967Search in Google Scholar

40. Guo X, Cheng S, Taylor KD, Cui J, Hughes R, Quinones MJ. Hypertension genes are genetic markers for insulin sensitivity and resistance. Hypertension 2005; 5:799–803.10.1161/01.HYP.0000154786.17416.eaSearch in Google Scholar

41. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 1993; 34:1367–83.10.1016/S0022-2275(20)36966-2Search in Google Scholar